Pharmacology, prescribing requirements, and patient preference are crucial factors in choosing opioid agonist treatments.

CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer ...

ES-SCLC patients show limited benefit from 3L therapies, highlighting the need for novel treatments to improve outcomes. SCLC is aggressive, often diagnosed at an extensive stage, and treated with ...

Please provide your email address to receive an email when new articles are posted on . Incidences of hospitalizations and surgeries were lowest with the vedolizumab-adalimumab sequence in UC and CD.

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...

The Food and Drug Administration has approved Onivyde with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma, the agency has ...

Substitution monotherapy and add-on therapy were equally effective as a second-line treatment for women with idiopathic generalized epilepsy, with no significant differences in failure rates between ...

Antihistamines are the first-line treatment for chronic spontaneous urticaria (CSU). If antihistamines are unsuccessful, systemic therapies that suppress the immune system are the next option. CSU is ...